Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for ...
See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...
16hon MSN
We recently compiled a list of the 10 Chinese Penny Stocks to Buy According to Analysts. In this article, we are going to ...
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...
Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.
The primary endpoint is overall survival (OS) in participants with PD-L1 TPS =50%. Secondary endpoints include OS in participants with PD-L1 TPS =1% and TPS 1-49%, progression-free survival (PFS), ...
Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...
The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.
Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...
The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...
Source: Getty Images Avelumab plus axitinib did not improve overall survival in the overall population or in patients with PD-L1-positive disease. The median overall survival was 44.8 months in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results